Please login to the form below

AMD

This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.

Life sciences and NHS feature in Johnson speech – but Brexit promises predominate

This was an apparent reference to Gyroscope, the company based in the Stevenage biotech cluster near London, which is testing its gene therapy for advanced dry Age-related Macular Degeneration (AMD).

Latest news

Novartis sees five new $1bn-plus launches in next two years

macular degeneration (AMD), ofatumumab for relapsing MS and fevpiprant for asthma.
Gyroscope advances gene therapy platform, merges with Orbit

approved therapies for the more common dry form of AMD. ... commercially”. He adds: “This marks an important step in fulfilling founding academics, David Kavanagh and Andrew Lotery’s vision of widespread use of genetically defined treatments for
Alnylam swaps Sanofi for Regeneron as R&D partner

Regeneron will however take the lead on eye disease candidates, a category in which it is already strong with blockbuster age-related macular degeneration (AMD) therapy Eylea (aflibercept), with Alnylam in
Novartis and Syncona back new Swiss biotech Anaveon

These include Freeline, which last year raised £88m to accelerate haemophilia gene therapy, and Gyroscope, which earlier this month dosed its first patient with its gene therapy for dry AMD, and
Gyroscope's gene therapy given to first dry AMD patient

Dry AMD is caused by the gradual death of retinal cells that can occur over many months or years and is far more common. ... We believe this is a great step forward in developing a therapy to treat dry AMD, while we continue our efforts on expanding our

More from news
Approximately 24 fully matching, plus 72 partially matching documents found.

Latest Intelligence

25 Women Leaders in UK Healthcare (part 2)

for advanced dry Age-related Macular Degeneration (AMD).
Deal Watch October 2018

RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... Effectively the deal is structured as an option, as the phase 2 study in dry AMD will be
30 Women Leaders in UK Healthcare (part 2)

treatments for age-related macular degeneration (AMD).
The good, the bad and the ugly

In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017,” says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated
Working with our healthcare system more closely is vital

to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

Gyroscope Therapeutics appoints CEO

Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director – UK Office: Excellent salary and benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Events Executive: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager – Healthcare advertising: Salary TBC

Client Services Director- Flexible Working: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Detecting Alzheimer’s ahead of a cure: A focus on promising new research...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Can you survive without the blue dot?: Or has the digital world has replaced our brain...